Nutritional status and long-term mortality in hospitalised patients with chronic obstructive pulmonary disease (COPD)

Patients with chronic obstructive pulmonary disease (COPD) often have difficulties with keeping their weight. The aim of this investigation was to study nutritional status in hospitalised Nordic COPD patients and to investigate the association between nutritional status and long-term mortality in this patient group. In a multicentre study conducted at four university hospitals (Reykjavik, Uppsala, Tampere and Copenhagen) hospitalised patients with COPD were investigated. Patient height, weight and lung function was recorded. Health status was assessed with St. George's Hospital Respiratory Questionnaire. After 2 years, mortality data was obtained from the national registers in each country. Of the 261 patients in the study 19% where underweight (BMI <20), 41% were of normal weight (BMI 20-25), 26% were overweight (BMI 25-30) and 14% were obese. FEV(1) was lowest in the underweight and highest in the overweight group (p=0.001) whereas the prevalence of diabetes and cardio-vascular co-morbidity went the opposite direction. Of the 261 patients 49 (19%) had died within 2 years. The lowest mortality was found among the overweight patients, whereas underweight was related to increased overall mortality. The association between underweight in COPD-patients, and mortality remained significant after adjusting for possible confounders such as FEV(1) (hazard risk ratio (95% CI) 2.6 (1.3-5.2)). We conclude that COPD patients that are underweight at admission to hospital have a higher risk of dying within the next 2 years. Further studies are needed in order to show whether identifying and treating weight loss and depletion of fat-free mass (FFM) is a way forward in improving the prognosis for hospitalised COPD patients.     

Leptin and TNF-alpha levels in patients with chronic obstructive pulmonary disease and their relationship to nutritional parameters

BACKGROUND: Leptin is a protein mainly secreted by adipocytes, and the major function of leptin was its role in body weight regulation. In humans, there was a strong correlation between leptin and nutritional parameters, such as body mass index (BMI) and fat mass (FM). Administration of recombinant leptin to OB/OB mice, which have a genetic defect in leptin production, reduces food intake, increases energy expenditure, and decreases body weight. It is suggested that increased levels of circulating leptin levels may contribute to anorexia and weight loss in pathologic conditions including chronic obstructive pulmonary disease (COPD). Recent studies have provided evidence for a link between leptin and proinflammatory cytokines such as TNF-alpha. OBJECTIVE: This study aimed to detect serum leptin and TNF-alpha levels in COPD patients without weight loss during stable disease and acute exacerbation, and to investigate relationships between leptin, TNF-alpha and nutritional parameters at different stages of the disease. MATERIAL AND METHODS: 26 stable COPD patients, 16 COPD patients with acute exacerbation and 15 control subjects participated in this study. To eliminate the effects of sex differences, all patients and controls were male. BMI, percent ideal body weight, percent FM, sum of skinfold thickness and serum leptin and TNF-alpha levels were measured in all participants. Leptin and TNF-alpha levels were measured by ELISA. RESULTS: Serum leptin and TNF-alpha levels were significantly higher in the patients experiencing exacerbation than in the stable patients and controls. Although leptin levels were lower and TNF-alpha levels were higher in the stable patient group than in the controls, these differences were not statistically different. Leptin levels were significantly correlated with the nutritional parameters in both control and stable groups. However, in patients with acute exacerbation, a correlation between leptin and nutritional parameters was not found. There was no significant relationship between TNF-alpha and nutritional parameters in the three groups. In addition, while there was no correlation between leptin and TNF-alpha levels in the stable and control groups, a significant positive correlation was observed in patients with exacerbation. CONCLUSION: In conclusion (1) elevated TNF-alpha levels may be related to increased inflammation in patients, (2) circulating TNF-alpha levels were associated with increased leptin levels and (3) although leptin and nutritional parameters were correlated in the stable COPD patients, the correlation was weaker compared to controls, and during an exacerbation it disappeared completely. Therefore, inappropriately increased levels of leptin and TNF-alpha noted during recurrent acute exacerbations in patients with COPD may lead to changes in nutritional parameters and body weight in the course of the disease.     

Chronic obstructive pulmonary disease and body mass index in five Latin America cities: the PLATINO study

BACKGROUND: The body mass index (BMI) is a prognostic factor for chronic obstructive pulmonary disease (COPD). Despite its importance, little information is available regarding BMI alteration in COPD from a population-based study. We examined characteristics by BMI categories in the total and COPD populations in five Latin-American cities, and explored the factors influencing BMI in COPD. METHODS: COPD was defined as a postbronchodilator forced expiratory volume in the first second/forced vital capacity (FEV(1)/FVC) <0.70. BMI was categorized as underweight (< 20 kg/m(2)), normal weight (20-24.9 kg/m(2)), overweight (25.0-29.9 kg/m(2)), and obese (> or = 30.0 kg/m(2)). RESULTS: Interviews were completed in 5571 subjects from 6711 eligible individuals, and spirometry was performed in 5314 subjects. There were 759 subjects with COPD and 4555 without COPD. Compared with the non-COPD group, there was a higher proportion of COPD subjects in the underweight and normal weight categories, and a lower proportion in the obese category. Over one-half COPD subjects had BMI over 25 kg/m(2). No differences in BMI strata among countries were found in COPD subjects. Factors associated with lower BMI in males with COPD were aging, current smoking, and global initiative for chronic obstructive lung disease (GOLD) stages III-IV, whereas wheeze and residing in Santiago and Montevideo were associated with higher BMI. In females with COPD, current smoking, lower education, and GOLD stages II-IV were associated with lower BMI, while dyspnea and wheeze were associated with higher BMI. CONCLUSIONS: BMI alterations are common in COPD with no significant differences among countries. Current smoking, age, GOLD stages, education level, residing in Santiago and Montevideo, dyspnea and wheeze were independently associated with BMI in COPD.     

Impact of body mass index on in-hospital outcomes following percutaneous coronary intervention (report from the New York State Angioplasty Registry)

Although obesity traditionally has been considered a risk factor for coronary revascularization, recent data from registry studies have shown a possible protective effect of obesity on outcomes after percutaneous coronary intervention (PCI). Using data from the New York State Angioplasty database over a 4-year period, we analyzed 95,435 consecutive patients who underwent PCI. Classification of body mass index (BMI) was: underweight (<18.5 kg/m(2)), healthy weight (18.5 to 24.9 kg/m(2)), overweight (25 to 29.9 kg/m(2)), moderate obesity (class I) (30 to 34.9 kg/m(2)), severe obesity (class II) (35 to 39.9 kg/m(2)), and very severe obesity (class III) (>40 kg/m(2)). In-hospital postprocedural mortality and complications were compared among these groups. Compared with healthy weight patients, patient with class I or II obesity had lower in-hospital mortality and major adverse cardiac events (MACE) (combined death, myocardial infarction, and emergency surgery), whereas patients at the extremes of BMI (underweight and class III obese patients) had significantly higher mortality and MACE rates. Adjusted hazards ratios for in-hospital mortality according to BMI were: underweight (2.69), healthy weight (1.0), overweight (0.90), class I obese (0.74), class II obese (0.67), and class III obese (1.63). Patients at the extremes of BMI (<18.5 and >40 kg/m(2)) were at increased risk of MACEs, including mortality after PCI, whereas patients who were moderately to severely obese (BMIs 30 to 40 kg/m(2)) were at lower risk than healthy weight patients.     

Weight, weight change, mortality in a random sample of older community-dwelling women

OBJECTIVE: To evaluate the relationship between measured weight, weight change, and 6-year mortality risk in a random sample of 648 community-dwelling women aged 65 and older from Baltimore, Maryland. MEASUREMENTS: Data were collected using a standardized questionnaire and administered in person by trained interviewers. Questionnaires were completed annually from 1984 to 1986, and body weight was measured at each interview. Weight was defined as body mass index (BMI) of low (< 23 kg/m2), average (> or = 23 kg/m2 to < or = 28 kg/m2), and high (> 28 kg/m2). Four mutually exclusive categories of weight change of at least 4.5% in BMI over the three annual interviews were developed to describe all possible weight change patterns: weight gain, weight loss, no change, and weight cycling. RESULTS: During the follow-up period, 106 women (16%) died. Women with low baseline BMI, regardless of weight change, and those who lost weight, regardless of baseline BMI had increased mortality risk. Women with average baseline BMI and weight loss had a very high mortality risk (hazard ratio (HR) 3.84, 95% Confidence interval (CI) 2.14-6.89). Women who weight cycled had increased mortality risk at low and high baseline weights, and a nonsignificant increased risk at average baseline weight (P = .069). Analyses were adjusted for age, education, smoking, alcohol usage, and pre-existing illness and included an interaction between weight change and baseline BMI. CONCLUSIONS: These results suggest that white, older, community-dwelling women are at an increased risk of mortality if they are underweight, lose weight, or weight cycle.     

COPD患者膳食摄入与去脂体质量指数的关系研究

目的 去脂体质量指数(fat-free mass index,FFMI)的减少是COPD的重要预估因素,本研究的目的主要是分析COPD患者营养状态与FFMI的关系.方法 根据2016年慢性阻塞性肺疾病全球倡议中COPD分组,选择分在C和D组的84例COPD男性患者,膳食摄入用食物频率问卷,评估身高、体质量、中上臂肌围(MUAC).数据由SPSS 18.0分析.结果 平均年龄(65.7±9.8)岁,所有患者中(21例)25.0％低于正常体质量(BMI＜21 kg/m2),(30例)35.7％的患者FFMI低于正常,FFMI＜ 16 kg/m2;与正常FFMI相比,在低FFMI患者中日常奶制品(t=-3.71,P=0.004)、红色肉类(t=-2.17,P=0.033)、水果(t=-3.97,P=0.002)摄入明显减少,正常FFMI的患者身高(t=-2.35,P=0.021)、体质量(t=-9.16,P=0.000)、MUAC(t=6.68,P=0.000)明显升高.结论 重视低FFMI的COPD患者,并评估营养状况、制订膳食策略,从而改善疾病的预后.     

Effect of lung volume reduction surgery (LVRS) on nutritional status in patients with COPD]

The beneficial effects of lung volume reduction surgery (LVRS) on patients with severe chronic obstructive pulmonary disease (COPD) on pulmonary function and exercise performance has been established. However, the impact on nutritional status and prognosis has not been demonstrated. In the present study, we investigated the changes in nutritional status in COPD patients undergoing bilateral thoracoscopic LVRS and also analyzed the relationship between nutritional status and postoperative complications and prognosis. After LVRS, body weight, fat-free mass (FFM) and caloric intake were significantly increased. Increase in FFM correlated significantly with improvement in exercise performance. In underweight patients before LVRS, the incidence of post-operative complications was significantly higher than in normal-weight patients, and a patient who was moderately-to-severely underweight (% ideal body weight < 80%) had a significantly poor prognosis. These findings suggest that improvement of nutritional status after LVRS contributes to improvement in exercise performance, and that preoperative nutritional status has a significant impact on postoperative morbidity and mortality. From our data, we concluded that preoperative nutritional assessment is an important part of the preoperative evaluation of LVRS, and that LVRS provides nutritional benefits for underweight patients with severe COPD.     

The energy intake that is needed for weight gain in COPD candidates for lung transplantation

Many patients with chronic obstructive pulmonary disease (COPD) have increased resting energy expenditure (REE) and may have an increased need for energy during activity. However, in terms of total energy balance, the influence of differences in REE may be compensated for by differences in daily energy expenditure. Energy needs may therefore be difficult to predict by measuring REE. The aim of this study was to predict the energy intake necessary for weight gain following dietary counselling. We studied 42 COPD patients (n = 27 underweight, n = 15 normal-weight) who were being considered for lung transplantation and had completed an intervention lasting a mean of 22 weeks. In the underweight patients, the dietary intervention consisted of dietary counselling for weight gain, while, in the normal-weight patients it focused on weight maintenance. It has been shown that a weight gain of over 2 kg in patients with COPD improves the prognosis and this was obtained in 52% of our patients. The mean (SD) increase in energy intake in the responders was 3448 (1310) kJ, while it was 635 (2454) kJ, p < 0.01 in the non-responders. Patients who used or had free access to nutritional supplements did not show greater success than patients who only used ordinary foods. Based on the relationship between the dependent variable (kg weight change) and the independent variable (energy intake), we can use linear regression to predict that an energy intake of 180% of REE predicted or 186 kJ/kg (44 kcal/kg) is necessary to obtain a weight gain of 2 kg.     

Risk of hospitalization associated with body mass index and weight changes among prevalent haemodialysis patients

The impact of body mass index (BMI) and body weight on hospitalization rates in haemodialysis patients is unknown.This study hypothesizes that being either underweight or obese is associated with a higher hospitalization rate.Observational study of 6296 European haemodialysis patients with prospective data collection and follow-up every six months for three years (COSMOS study). The risk of being hospitalized was estimated by a time-dependent Cox regression model and the annual risk (incidence rate ratios, IRR) by Poisson regression. We considered weight loss, weight gain and stable weight. Weight change analyses were also performed after patient stratification according to their baseline BMI.A total of 3096 patients were hospitalized at least once with 9731 hospitalizations in total. The hospitalization incidence (fully adjusted IRR 1.28, 95% CI [1.18–1.39]) was higher among underweight patients (BMI <20 kg/m²) than patients of normal weight (BMI 20–25 kg/m²), while the incidence of overweight (0.88 [0.83–0.93]) and obese patients (≥30 kg/m², 0.85 [0.79–0.92]) was lower. Weight gain was associated with a reduced risk of hospitalization. Conversely, weight loss was associated with a higher hospitalization rate, particularly in underweight patients (IRR 2.85 [2.33–3.47]).Underweight haemodialysis patients were at increased risk of hospitalization, while overweight and obese patients were less likely to be hospitalized. Short-term weight loss in underweight individuals was associated with a strikingly high hospitalization rate.     

The impact of body mass index on inpatient- versus outpatient-treated chronic obstructive pulmonary disease exacerbations

BACKGROUND:

Increased body weight has been associated with worse prognoses for many chronic diseases; however, this relationship is less clear in patients with chronic obstructive pulmonary disease (COPD), with underweight patients experiencing higher morbidity than normal or overweight patients.

OBJECTIVE:

To assess the impact of body mass index (BMI) on the risk for COPD exacerbations.

METHODS:

The present study included 115 patients with stable COPD (53% women; mean [± SD] age 67±8 years). Height and weight were measured to calculate BMI. Patients were followed for a mean of 1.8±0.8 years to assess the prospective risk of inpatient-treated exacerbations and outpatient-treated exacerbations, all of which were verified by chart review.

RESULTS:

Cox regression models revealed that underweight patients were at greater risk for inhospital-treated exacerbations (RR 2.93 [95% CI 1.27 to 6.76) relative to normal weight patients. However, overweight (RR 0.59 [95% CI 0.33 to 1.57) and obese (RR 0.99 [95% CI 0.53 to 1.86]) patients did not differ from normal weight patients. All analyses were adjusted for age, sex, length of diagnosis, smoking pack-years, forced expiratory volume in 1 s, and time between recruitment and last exacerbation. BMI did not influence the risk of out-of-hospital exacerbations.

CONCLUSIONS:

The present study showed that underweight patients were at greater risk for inhospital exacerbations. However, BMI did not appear to be a risk factor for out-of-hospital exacerbations. This suggests that the BMI-exacerbation link may differ according to the nature of the exacerbation, the mechanisms for which are not yet known.     

Global variability in angina pectoris and its association with body mass index and poverty

In the absence of a previous global comparison, we examined the variability in the prevalence of angina across 52 countries and its association with body weight and the poverty index using data from the World Health Organization-World Health Survey. The participants with angina were defined as those who had positive results using a Rose angina questionnaire and/or self-report of a physician diagnosis of angina. The body mass index (BMI) was determined as the weight in kilograms divided by the square of the height in meters. The poverty index (a standard score of socioeconomic status for a given country) was extracted from the United Nations' statistics. The associations of angina with the BMI and poverty index were analyzed cross-sectionally using univariate and multivariate analyses. The results showed that the total participants (n = 210,787) had an average age of 40.64 years. The prevalence of angina ranged from 2.44% in Tunisia to 23.89% in Chad. Those participants with a BMI of <18.5 kg/m(2) (underweight), 25 to 29 kg/m(2) (overweight), or BMI ≥ 30 kg/m(2) (obese) had a significantly greater risk of having angina compared to those with a normal BMI (≥ 18.5 but <25 k/m(2)). The odds ratios of overweight and obese for angina remained significant in the multilevel models, in which the influence of the country-level poverty status was considered. A tendency was seen for underweight status and a poverty index >14.65% to be associated with the risk of having angina, although these associations were not statistically significant in the multilevel models. In conclusion, significant variations were found in the anginal rates across 52 countries worldwide. An increased BMI was significantly associated with the odds of having angina.     

Low Body Mass Index Is Associated with Higher Odds of COPD and Lower Lung Function in Low- and Middle-Income Countries

The relationship of body mass index (BMI) with lung function and COPD has been previously described in several high-income settings. However, few studies have examined this relationship in resource-limited settings where being underweight is more common. We evaluated the association between BMI and lung function outcomes across 14 diverse low- and middle-income countries. We included data from 12,396 participants aged 35–95 years and used multivariable regressions to assess the relationship between BMI with either COPD and lung function while adjusting for known risk factors. An inflection point was observed at a BMI of 19.8?kg/m². Participants with BMI < 19.8?kg/m² had a 2.28 greater odds (95% CI 1.83–2.86) of having COPD and had a 0.21 (0.13–0.30) lower FEV₁ and 0.34 (0.27–0.41) lower FEV₁/FVC z-score compared to those with BMI ≥ 19.8?kg/m². The association with lung function remained even after excluding participants with COPD. Individuals with lower BMI were more likely to have COPD and had lower lung function compared to those in higher BMI. The association with lung function remained positive even after excluding participants with COPD, suggesting that being underweight may also play a role in having worse lung function.     

慢性阻塞性肺疾病患者体质量指数与肺功能及HRCT气道重塑参数的相关性研究

目的探讨低体质量指数（bodymassindex,BMI）cOPD患者肺功能受损程度、临床及影像学特征。方法选取COPD急性加重期患者62例,根据BMI分为4组：低体重组（BMI％18．5kg／m2）、正常体重组（BMI18．5～23．9kg／m2）、超重组（BMI24．0H27．9kg／m2）、肥胖组（BMI≥28kg／m2）。所有患者进行慢性阻塞性肺疾病自我评估测试（COPDassessmenttest,CAT）问卷、肺功能检测及高分辨CT（highresolutionCT,HRcT）检查,并同时应用HRCT相关软件测定肺气肿评分、气道壁厚度及管腔面积等气道重塑指标。观察各组上述指标的变化,并研究其与BMI的相关性。结果①所有患者中低体重组患者12例,正常体重组患者30例,超重组患者7例,肥胖组患者13例,各组患者的年龄、性别、吸烟指数差异无统计学意义;②与正常体重、超重及肥胖患者比较,低体重患者FEV。％pred、MVV、Dt．co／VA％pred、FEV,／FVC均下降（P〈0．05）,而RV／TLc增高（P〈0．05）;③与正常体重、肥胖患者比较,低体重患者CAT评分增高（Pd0．05）;④与正常体重、超重及肥胖组患者比较,低体重组患者肺气肿评分高（Pd0．05）;⑤低体重患者管壁面积百分比（WA％pred）、壁厚与外径比率（TDR％pred）与各组间差异无统计学意义（P〉0．05）;⑥BMI与CAT评分、肺气肿评分、RV／TLC均呈负相关（r=-0．351,P〈0．05;r=-0．628,P〈0．05;r=-0．256,P〈0．05）,而与WA％pred、TDR％pred无相关性（P〉0．05）;BMI与FEV1／FVC、DLCO／VA％pred呈正相关（r=0．387,P〈0．05;r=0．549,P〈0．05）。结论低BMI的COPD患者肺气肿程度严重,通气及弥散功能明显下降,这对临床综合评估COPD病情的严重程度有一定帮助。     

Body mass index, prognosis and mode of death in chronic heart failure: results from the Valsartan Heart Failure Trial

AIMS: To assess the relationship between body mass index (BMI), mortality and mode of death in chronic heart failure (CHF) patients; to define the shape of the relationship between BMI and mortality. METHODS AND RESULTS: We performed a post-hoc analysis of 5010 patients from the Valsartan Heart Failure Trial. The end-points of the study were all-cause and cardiovascular mortality. Mortality rate was 27.2% in underweight patients (BMI<22 kg/m2), 21.7% in normal weight patients (BMI 22-24.9 kg/m2), 17.9% in overweight patients (BMI 25-29.9 kg/m2) and 16.5% in obese patients (BMI>30 kg/m2) (p<0.0001). The rates of non-cardiovascular death did not differ among groups. The risk of death due to progressive heart failure was 3.4-fold higher in the underweight than in the obese patients (p<0.0001). Normal weight, overweight and obese patients had lower risk of death as compared with underweight patients (p=0.019, HR 0.76, 95% CI 0.61-0.96; p=0.0005, HR 0.68, 95% CI 0.55-0.84; p=0.003, HR 0.67, 95% CI 0.52-0.88, respectively) independently of symptoms, ventricular function, beta-blocker use, C-reactive protein and brain natriuretic peptide levels. CONCLUSIONS: In CHF patients a higher BMI is associated with a better prognosis independently of other clinical variables. The relationship between mortality and BMI is monotonically decreasing.     

Dietary support to underweight patients with end-stage pulmonary disease assessed for lung transplantation

BACKGROUND: Undernutrition in hospitalized patients is often not recognized and nutritional support neglected. Chronic obstructive pulmonary disease is frequently characterized by weight loss. No data exist on the effects of nutritional supplementation in underweight lung transplantation candidates during hospitalization. OBJECTIVE: To evaluate the effects on energy intake and body weight of an intensified nutritional support compared to the regular support during hospitalization. METHODS: The participants were underweight (n = 42) and normal-weight (n = 29) patients with end-stage pulmonary disease assessed for lung transplantation. The underweight patients were randomized to receive either an energy-rich diet planned for 10 MJ/day and 45-50 energy percentage fat and offered supplements (group 1), or the normal hospital diet planned for 8.5-9 MJ/day and 30-35 energy percentage fat and regular support (group 2, control group). The normal-weight control patients (group 3) received the normal diet. Food intake was recorded for 3 days. RESULTS: During a mean hospital stay of 12 days, the energy intake was significantly greater for the patients on intensified nutritional support (median 11.2 MJ) than for the underweight patients on the regular support (8.4 MJ; p < 0.02) and the normal-weight patients (7.0 MJ; p < 0.001). The increase in energy intake in group 1 resulted in a significant weight gain (median 1.2 kg) compared with group 2 (p < 0.01) and group 3 (p < 0.001). CONCLUSIONS: In a group of underweight patients with lung disease assessed for lung transplantation, it was possible to increase energy intake by an intensified nutritional support which was associated with a significant weight gain, compared to the regular nutritional support during a short hospital stay.     

体重指数与慢性阻塞性肺疾病及生活质量的关系

目的在2002至2004年中国7个地区（北京、上海、广东、辽宁、天津、重庆和陕西）慢性阻塞性肺疾病（COPD）现况调查的基础上，探讨体重指数（BMI）与COPD的关系。方法现况调查采用多阶段分层整群随机抽样方法，对40岁及以上的居民进行问卷调查、身高和体重的测量及肺功能检测。调查有效人数为20245名，男8705名，女11540名，以支气管扩张试验后第一秒用力呼气容积／用力肺活量（FEV1／FVC）〈70％作为COPD的诊断标准，并排除其他已知的气流受限的疾病，共筛查出1668例COPD和18577例非COPD进行BMI与COPD的关系分析。结果COPD患者的BMI[（22．7±3．5）kg／m^2]较非COPD患者[（24．1±3．4）kg／m^2]低，吸烟者BMI为[（23．6±3．4）kg／m^2]较不吸烟者[（24．2±3．5）ks／m^2]低，差异均有统计学意义（F分别为158．31、49．10，P均〈0．01），且COPD与吸烟存在对BMI的交互作用（F=6．03，P〈0．05）。COPD病情程度分级越高BMI越低（F=45．46，P〈0．01），COPD病情程度分级与BMl分级存在负相关（r=-0．08，P〈0．01）。BMI越低COPD的患病率越高（趋势x^2=102．68，P〈0．01），多因素logistic回归分析显示，与正常BMI（18．5～23．9kg／m^2）比较，1级BMI（〈18．5kg／m^2）、3级BMI（24．0～27．9kg／m^2）和4级BMI（≥28．0ks／m^2）患COPD的D尺值分别为[2．12（1．73～2．59）、0．67（0．59～0．76）、0．60（0．49～0．73），P均〈0．05]；且BMl分级与吸烟存在对COPD的交互作用（x^2=4．73，P〈O．05）。与2级BMI的COPD患者比较，1级BMI的COPD患者生活质量差（心理指数评分：55±8、57±6，F=2．96，P〈0．05；躯体指数评分：42±10、46±9，F=4．21，P〈0．01）；气促分数高（1．4±1．5、1．1±1．3，x^2=14．32，P〈0．01）。结论1级BMI与COPD关系密切，其可能是COPD患病的独立于吸烟的危险因素，而低BMI也可能是COPD病情严重程度的一个重要指标。     

Nutritional status of COPD patients with acute exacerbation

The prevalence and features of nutritional status in patients with chronic obstructive pulmonary disease (COPD) have been studied extensively in stable conditions, but are poorly defined in the presence of an acute exacerbation. The aim of this study is to evaluate the nutritional status of COPD patients with acute exacerbation and possible relationship between nutritional parameters and pulmonary functions. The study group consisted of 53 COPD patients acutely admitted to the hospital for standardized medical treatment. The nutritional status of patients was assessed by anthropometric measurements, biochemical analysis, and immunologic testing. The patients were divided into two groups as having severe (FEV1 < 50%) and mild to moderate (FEV1 ? 50%) COPD and weight loss greater than 5% for the comparison of the study parameters. Ideal body weight (IBW%) was found as 104.42 +/- 4.30 in severe COPD, where as it was 115.31 +/- 7.28 in mild to moderate COPD group (p= 0.07). There was no relationship demonstrated between IBW% and FEV1. IBW% was correlated with DLCO for the total study population (r= 0.353, p= 0.035). Weight loss greater than 5% of body weight (BW) was observed in 54% of patients. Comparison of the patient's actual weight to their usual weight revealed statistically significant weight loss (p< 0.01). Mean values of serum albumin, transferrin were found in normal range. Delayed type hypersensitivity skin test revealed normal immune status. When the study parameters were compared, no any statistically significant differences in parameters related to nutritional status were detected, between severe and mild to moderate COPD groups. As a statistically significant weight loss was found between the actual and usual weights of the patients, monitoring of nutritional parameters and eventual dietetic treatment should also be included in the goals of the medical treatment of patients with COPD in acute exacerbation.     

Elevated circulating plasma adiponectin in underweight patients with COPD

BACKGROUND: Adiponectin is an adipose tissue-derived specific protein that has antiinflammatory as well as anti-atherosclerotic effects. In the United States, many patients with COPD are obese and die of cardiovascular diseases. However, in Japan, patients with COPD are frequently cachexic and die of respiratory failure. This study was designed to investigate the role of adiponectin in these differences in characteristics of COPD. METHODS: We enrolled normal-weight and underweight male patients with COPD (n = 31; age, 71 +/- 1 years; body mass index [BMI], 20.1 +/- 0.6 kg/m(2)) and age-matched, healthy, male, control subjects (n = 12). The adiponectin levels were measured by enzyme-linked immunosorbent assay. Correlation of adiponectin levels with pulmonary function and serum levels of proinflammatory cytokines (tumor necrosis factor [TNF]-alpha and interleukin-6) were estimated. RESULTS: Adiponectin levels in patients with COPD were significantly higher than those in control subjects (p<0.01) and inversely correlated with BMI (r = - 0.55, p<0.01). Even in the normal-weight patients with COPD, adiponectin levels were significantly higher than those in control subjects (p<0.01). Adiponectin levels in patients with COPD significantly correlated with percentage of predicted residual volume (r = 0.40, p<0.05). In patients with TNF-alpha levels > 5 pg/mL, there was a significant correlation between plasma adiponectin and serum TNF-alpha levels (r = 0.68, p<0.05). CONCLUSIONS: Plasma adiponectin levels in patients with COPD were elevated and correlated with body weight loss, hyperinflation, and systemic inflammation. Increased adiponectin may reduce cardiovascular events in underweight patients with COPD.     

Impact of obesity as a mortality predictor in high-risk patients with myocardial infarction or chronic heart failure: a pooled analysis of five registries

AIMS: To explore the influence of obesity on prognosis in high-risk patients with myocardial infarction (MI) or heart failure (HF). METHODS AND RESULTS: Individual data of 21 570 consecutively hospitalized patients from five Danish registries were pooled together. After a follow-up of 10.4 years, all-cause mortality using multivariate model and adjusted hazard ratios (HR) with 95% confidence intervals were calculated. Compared with normal weight [body mass index (BMI) 18.5-24.9 kg/m2], obesity class II (BMI >or= 35 kg/m2) was associated with increased risk of death in patients with MI but not HF [HR = 1.23 (1.06-1.44), P = 0.006 and HR = 1.13 (0.95-1.36), P = 0.95] (P-value for interaction = 0.004). Obesity class I (BMI 30-34.9 kg/m2) was not associated with increased risk of death in MI or HF [HR = 0.99 (0.92-1.08) and 1.00 (0.90-1.11), P > 0.1]. Pre-obesity (BMI 25-29.9 kg/m2) was associated with decreased death risk in MI but not HF [HR = 0.91 (0.87-0.96), P = 0.0006 and 1.04 (0.97-1.12), P = 0.34] (P-value for interaction = 0.007). Underweight (BMI < 18.5 kg/m2) patients were in increased death risk regardless of MI or HF [HR = 1.54 (1.35-1.75) and 1.37 (1.18-1.59), P < 0.001]. CONCLUSION: In patients with MI but not HF, the relationship between BMI and mortality is U-shaped with highest mortality in underweight and obese class II, but lowest in the other BMI classes.     

Prospective evaluation of laparoscopic Roux en Y gastric bypass in patients with clinically severe obesity

AIM： To evaluate and present our experience with laparoscopic Roux en Y gastric bypass （RYGB） in a selected patient population.
METHODS： A cohort of 130 patients with a body mass index （BMI） between 35 and 50 kg/m^2 were evaluated in relation to postoperative morbidity, weight loss and resolution of co-morbidities for a period of 4 years following laparoscopic RYGB.
RESULTS： Early morbidity was 10.0%, including 1 patient with peritonitis who was admitted to Intensive Care Unit （ICU） and 1 conversion to open RYGB early in the series. There was no early or late mortality. Maximum weight loss was achieved at 12 mo postoperatively, with mean BMI 30 kg/m^2, mean percentage of excess weight loss （EWL%） 66.4% and mean percentage of initial weight loss （IWL%） 34.3% throughout the follow-up period. The majority of preexisting comorbidities were resolved after weight loss and no major metabolic disturbances or nutritional deficiencies were observed.
CONCLUSION： Laparoscopic RYGB appears to be a safe and effective procedure for patients with BMI 35-50 kg/m^2 with results that are comparable to previously published data mostly from the USA but from Europe as well.